ABSTRACT
DUAs with all cancer types, the initiation, development, and metastatic stages of prostate and colorectal cancers, are very important to understand the relationship between tumor cells and normal cells in the stroma, the changes in gene and signaling pathways, as well as their behavior towards the immune response. Therefore, for experimental research, the formation of tumor cell lines, the formation of tissues in the laboratory environment, and the formation of tumor models via injection or implantation of animal or human tumor cells or tissues in experimental animals, which are the silent heroes of science, and their molecular imaging are very important. Only in this way can there be an effective treatment of these diseases, or they can be prevented before they occur.
References
1Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol 2013;10:483-487.
2Yoshimoto M, Cutz JC, Nuin PA, et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genet Cytogenet 2006;169:128-137.
3Cuzick J, Yang ZH, Fisher G, et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013;108:2582-2589.
4Huang Y, Cheng C, Zhang C, et al. Advances in prostate cancer research models: From transgenic mice to tumor xenografting models. Asian J Urol 2016;3:64-74.
5Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243-6249.
6Corn PG. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res 2012;4:183-193.
7Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical Mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 2010.
8Hafeez BB, Zhong W, Fischer JW, et al. Plumbagin, a medicinal plant (Plumbago zeylanica)-derived 1,4-naphthoquinone, inhibits growth and metastasisof human prostate cancer PC-3M-luciferase cells in anorthotopic xenograft mouse model. Mol Oncol 2013;7:428-439.
9Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nüde mouse model. Cancer Res 2008;68:3323-3333.
10Hayward SW, Dahiya R, Cunha GR, Bartek J, Deshpande N, Narayan P. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1. In Vitro Cell Dev Biol Anim 1995;31:14-24.
11Jiang M, Strand DW, Fernandez S, et al. Functional remodeling for benign human prostatic tissues in vivo by spontaneously immortalized progenitor and intermediate cells. Stem Cells 2010;28:344-356.
12Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014;345:124-125.
13Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev 2014;24:68-73.
14Lin D, Wyatt AW, Xue H, et al. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 2014;74:1272-1283.
15Choi SY, Lin D, Gout PW, Collins CC, Xu Y, Wang Y. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev 2014;79:222-237.
16Garber K. From human to mouse and back: ’tumorgraft’ models surge in popularity. J Natl Cancer Inst 2009;101:6-8.
17Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
18Corbett TH, Griswold DP Jr, Roberts BJ, et al. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35:2434-2439.
19Brattain MG, Strobel-Stevens J, Fine D, et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980;40:2142-2126.
20Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 2011;141:1762-1772.
21Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-4239.
22Hidalgo M, Bruckheimer E, Rajeshkumar NV, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311-1316.
23Cunha L1, Horvath I, Ferreira S, et al. Preclinical imaging: an essential ally in modern biosciences. Mol Diagn Ther 2014;18:153-173.
24Weissleder R, Mahmood U. Molecular imaging. Radiology 2001;219:316-333.
25Grassi R, Lagalla R, Rotondo A. Genomics, proteomics, MEMS and SAIF: which role for diagnostic imaging? Radiol Med 2008;113:775-778.
26Ramírez de Molina A, Gutiérrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002;21:4317-4322.
27Hara T, Bansal A, DeGrado TR. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F] FDG in cultured prostate cancer cells. Nucl Med Biol 2006;33:977-984.
28Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 2013;63:1040-1048.
29Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med 2013;38:305-314.
30Vāvere AL, Kridel SJ, Wheeler FB, Lewis JS. 1-11C-Acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 2008;49:327-334.
31Emonds KM, Swinnen JV, Lerut E, Koole M, Mortelmans L, Mottaghy FM. Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model. EJNMMI Res 2013;3:31.
32Mohsen B, Giorgio T, Rasoul ZS, et al. Application of C- 11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. BJU Int 2013;112:1062-1072.
33Wibmer AG, Burger IA, Sala E, Hricak H, Weber WA, Vargas HA. Molecular Imaging of Prostate Cancer. Radiographics 2016;36:142-159.
34Yu CY, Desai B, Ji L, Groshen S, Jadvar H. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging 2014;4:580-601.
35Burgio SL, Fabbri F, Seymour IJ, Zoli W, Amadori D, De Giorgi U. Perspectives on mTOR inhibitors for castration-refractory prostate cancer. Curr Cancer Drug Targets 2012;12:940-949.
36Nuñez R, Macapinlac HA, Yeung HW, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002;43:46-55.
37Puccetti L, Supuran CT, Fasolo PP, et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. Eur Urol 2005;48:215-221.
38Kälkner KM, Ginman C, Nilsson S, et al. Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma. Nucl Med Biol 1997;24:319-325.
39Tehrani OS, Muzik O, Heilbrun LK, et al. Tumor imag¬ing using 1-(2’-deoxy-2’-18F-fluoro-b-d-arabinofuranosyl) thymine and PET. J Nucl Med 2007;48:1436-1441.
40Vargas HA, Wassberg C, Fox JJ, et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 2014;271:220-229.
41Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-6362.
42Gornik G, Mansi R, Abiraj K, et al. Evaluation of the GRPR radioantagonist Cu-64-CB-TE2A-AR-06 in mice and men [abstr]. J Nucl Med 2011;52(Suppl 1):22.
